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between projected costs across methods was statistically
signiﬁcant (Kappa > 0.80, p < 0.001) in each head-to-
head comparison, conﬁrming the feasibility of using the
LR to approximate the results of the decision analysis.
CONCLUSIONS: Both methods demonstrate that glip-
izide GITS is the least expensive ﬁrst-line therapy for
newly diagnosed Type-2 diabetes patients, followed by
metformin and rosiglitazone. The LR can be used as a
quick and easy tool for use in approximation of the more
comprehensive decision tree.
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OBJECTIVE: The goal of this study was to compare
resource utilization for two insulin delivery devices:
InnoLet® and vial/syringe. METHODS: Diabetic patients
requiring assistance with insulin injections (vision and/
or motor impairments) were followed over two 6-week
periods in a randomized crossover study to estimate the
resource utilization associated with different insulin deliv-
ery systems: the InnoLet® insulin doser or the vial and
syringe. A total of 79 patients were enrolled in the study.
Resource utilization was measured as the number of visits
per day which the nurse/caregivers needed to have with
the patient in order to assist (if required) with an injec-
tion, times the costs for such a visit ($80/hour; minimum
visit 1 hour based on local visiting nursing rate) plus the
daily cost for insulin. RESULTS: The mean age of patients
was 68.2 ± 8.6 years, with a mean A1c level of 7.5 ± 1.4
at baseline. Patients were previously treated with
vial/syringe and required assistance with making injec-
tions. Reported major hypoglycemic events occurred as
frequently with both treatments. The mean daily costs for
home visits associated with the injections were $99 and
$179 for the InnoLet and vials/syringe patients, respec-
tively (p < 0.001). Fifty-three percent of the patients
became independent of nursing/caregiver assistance for
the injections when using InnoLet®. Furthermore, the
mean time spent by nurses or caregivers for assisting in
injection preparation was lower for patients using the
InnoLet doser than for the vial and syringe. CONCLU-
SIONS: Patients using the InnoLet® doser required sig-
niﬁcantly fewer visits from nurses/caregivers, resulting in
less resource utilization, and use of InnoLet® fostered
independence in patients who had difﬁculty with self-
injection using vial and syringe.
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Becaplermin (Regranex®), a recombinant human
platelet-derived growth factor, and graftskin (Apligraf®),
a bilayered tissue-engineered human skin equivalent,
promote the local wound healing process and therefore
reduce the time to complete healing and rate of amputa-
tion of lower extremity in diabetic foot ulcer patients.
However, very limited information is available for the rel-
ative cost-effectiveness of these new treatments. OBJEC-
TIVES: To evaluate the cost-effectiveness of graftskin plus
standard foot care and becaplermin plus standard foot
care in comparison to the standard foot care alone from
the societal perspective. METHODS: A decision analysis
model was built for chronic diabetic foot ulcer patients.
Study period was one year. The effectiveness was mea-
sured in quality-adjusted-life years (QALYs). Data for
QALYs, transition probabilities, efﬁcacy, and costs were
taken mostly from the literature. All costs were adjusted
to 2002 US dollars. Sensitivity analyses were performed
on important parameters including costs and efﬁcacy 
of graftskin and becaplermin, and costs of amputation.
RESULTS: In the base case analysis, graftskin was a dom-
inant strategy over becaplermin and standard care. Also,
becaplermin was the dominant strategy over standard
care alone. Compared to the standard care group and the
becaplermin group, the graftskin group had higher
QALYs (difference was 0.03 and 0.06, respectively). In
terms of savings of medical costs, the graftskin group
gained $2202 and $179, compared to the standard care
group and the becaplermin group during the study
period. The results of the sensitivity analysis were con-
sistent with the results of the base case analysis. CON-
CLUSIONS: Although the standard care costs less at the
initial state, patients receiving the standard care only are
more likely to have costly outcomes compared to patients
receiving graftskin or becaplermin, and this translates
into higher expected costs. Also, results indicate that
treating diabetic foot ulcer patients with graftskin was
more cost-effective than treating with becaplermin.
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OBJECTIVES: The primary objective of the Diabcost
study was to determine the cost of type 2 diabetes in 
Australia. Additional objectives were to collect data on
quality of life, health service use and indirect costs for
people with type 2 diabetes, and to improve understand-
ing of the burden on carers. METHODS: A paper-based
questionnaire was used to collect cross-sectional survey
data. Approximately 25,000 questionnaires were mailed
to people on a national diabetes database and responses
were received from 10,652 people. Respondents were
asked to self-report three months’ retrospective data.
Questions covered demographic information, health
status (including history of microvascular and macrovas-
cular complications), health service utilisation, cost to
people with diabetes, lost productivity and quality of life
(EQ-5D). A separate questionnaire ﬁlled in by carers
covered carer burden. Derivation of costs used a combi-
nation of costs and charges. RESULTS: The mean annual
cost per individual with type 2 diabetes was $A7565.
There were direct costs of $A5325 (comprising $A4260
in health care and $A1065 in non health care costs). Self-
reported indirect costs were $A35 and carer costs were
$A2150. When the population was divided into four
groups based on history of complications, it was clear
that more complications resulted in higher average costs.
The cost for respondents with no complications was
$A4025, with microvascular complications only was
$A7025, with macrovascular complications only 
was $A9055 and with both complications was $A9645.
Utilities and quality of life also differed for the four
groups. The overall cost of type 2 diabetes in Australia
was calculated to be $A3 billion. CONCLUSIONS: Type
2 diabetes impacts signiﬁcantly on affected individuals
and their carers. Onset of macrovascular and microvas-
cular complications increases the burden of illness
through deterioration in quality of life and increased costs
to the community.
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OBJECTIVE: To develop a model to evaluate the cost-
effectiveness of starting patients with Diabetes Mellitus
on lifelong therapy with ACE-Is immediately on diagno-
sis. Although apparently already a dominant strategy for
renal protection in diabetes, ACE-Is are not prescribed to
patients immediately on diagnosis of Type II diabetes.
Determining whether they have overall cost-effectiveness
in preventing cardiac endpoints may be useful in updat-
ing treatment guidelines. METHODS: Interventions:
Treating patients with DM with ACE-Is immediately on
diagnosis vs. not using ACE-Is. Design: Age-speciﬁc life-
time costs and QALYs associated with each of the end-
points: MI, stroke and ESRD, were estimated for each
intervention strategy. Time Horizon: Lifetime. Perspec-
tive: Societal. Target Population: The model was esti-
mated in females aged 40 and over. Model measures:
discounted lifetime cost, discounted quality-adjusted 
life expectancy for each strategy. Incremental cost-
effectiveness ratio. Data Sources: Randomized control
trials estimating the effect of ACE-Is on the occurrence of
each endpoint, life tables for mortality and life expectancy
data, epidemiological and observational studies to esti-
mate the added risk for each endpoint contributed by dia-
betes, and quality of life/health utility studies to estimate
QALYs associated with each endpoint. RESULTS: Base-
Case Analysis: Immediately starting therapy with ACE-Is
was shown to be a dominant strategy. Starting from age
40, this strategy would save total discounted lifetime costs
of $63,835 and improve discounted quality-adjusted 
life expectancy by almost 2 years. Sensitivity Analysis:
Although still indicating a dominant strategy, both life-
time costs and QALYs are sensitive to the discount rate
used, and lifetime costs are highly sensitive to the lifetime
cost of ESRD management. CONCLUSIONS: Starting all
patients with Type II DM on lifelong ACE-I therapy is a
simple strategy that provides greater beneﬁt at a lower
cost. It may be worth considering its implementation as
a standard diabetes patient management strategy.
PDB18
ESTIMATING THE COST-EFFECTIVENESS OF
REPAGLINIDE PLUS METFORMIN VS.
NATEGLINIDE PLUS METFORMIN OVER A 
30-YEAR PERIOD
Nicklasson L1, Palmer A2, Gall MA3, Roze S2
1Novo Nordisk Pharmaceuticals, Princeton, NJ, USA; 2CORE
Center for Outcomes Research, Basel, Switzerland; 3Novo
Nordisk A/S, Bagsvaerd, Denmark
OBJECTIVES: To simulate the cost-effectiveness of two
different treatment regimens for type 2 diabetes patients.
METHODS: Cost-effectiveness was measured as cost per
life years gained (LYG) and cost per quality adjusted life
years gained (QALY). A standard Monte Carlo simula-
tion combining published literature for risk of long-term
diabetic complications with risk functions for each com-
plication was used. Clinical outcomes were based upon
the following long-term diabetic complications: cardio-
vascular, neuropathy, nephropathy, and retinopathy. Life-
time costs were calculated as the yearly costs for drugs
plus cost for complications (US Medicare perspective)
over a 30-year period, and clinical outcomes and lifetime
costs were discounted at 3%. Patient baseline data were
taken from a randomized, multicenter trial, comparing a
treatment regimen of repaglinide plus metformin vs.
nateglinide plus metformin for type 2 diabetic patients.
After dose adjustments to achieve glycemic targets,
median ﬁnal daily doses were 5mg repaglinide and 
360mg nateglinide. RESULTS: The reduction in A1c
values from baseline was -1.28% point (p < 0.001) and
